Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Chinook Therapeutics Inc
KDNY
Healthcare
Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase...
III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:KDNY)
New Post
View:
Posts & Comments
Threaded Posts
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Sep 01, 2021 7:08am
5 BIOTECH STOCKS INSIDERS ARE BUYING!
$KRON $EYEN $PRLD $NBSE $KDNY Insider selling or buying cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a
...more
(78)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Feb 18, 2019 9:01pm
it was a buy for me last week
on Friday afternoon,at $4 per share,this is a turnaround situation with the technicals forming a base and the bottom is past,so glta shareholders for the steady climb up.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden